Formulation And Evaluation of Allylamine Agent For Nail Preparation For Management Of Fungal Infection
Keywords:
DSC study allylamine agentAbstract
In this research, a medicated antifungal nail polish containing Terbinafine and Clobetasol propionate was developed. Long-term, sustained release of Terbinafine and Clobetasol propionate was investigated in the hopes of lowering the frequency of dosing. Toenail fungus, also known as onychomycosis, is quite common. Infection with dermatophytes, Candida, or non-dermatophytic molds can lead to onychomycosis. In terms of non-volatile content, drug release, drug content estimate, and inhibitory zone, the optimum formulation was a nail lacquer comprising 1-2 percent Terbinafine and Clobetasol propionate, as well as 3 percent ethyl cellulose. Up to 48 hours after administration, 98.12% of the drug was still active. FTIR tests confirmed that the drug and excipient were safe to use together. It was expected that this would improve clinical efficacy and patient compliance. The nail polish formulations were created by simply combining the necessary ingredients together, and then evaluated for non-volatile content, flowability, drug diffusion studies, and an estimate of the drug content. The selected optimized formulation, F4, showed no significant change in initial attributes throughout a month-long accelerated stability analysis performed at 40-20°C in accordance with ICH norms. The development and deployment of these systems pose no known dangers. Antifungal nail lacquer is a potential novel dosage form in the healthcare and pharmaceutical industries.
Downloads
References
Aggarwal, Rohan, Monika Targhotra, P. K. Sahoo, and Meenakshi K. Chauhan. "Onychomycosis: Novel strategies for treatment." Journal of Drug Delivery Science and Technology 57 (2020): 101774.
Alam G, Singh MP, Singh A, Vishwakarma DK, Patel R, Srivastava SP. Transungual drug transport: advancement and challenges. J Pharm Res 2012;5(5):2574-79.
Baden, Howard P., Lowell A. Goldsmith, and Barbara Fleming. "A comparative study of the physicochemical properties of human keratinized tissues." Biochimica et Biophysica Acta (BBA)-Protein Structure 322, no. 2 (1973): 269-278.
Baker, Stephen J., Xiaoying Hui, and Howard I. Maibach. "Progress on new therapeutics for fungal nail infections." Annual Reports in Medicinal Chemistry 40 (2005): 323.
Bohn, Manfred, and Karl Th Kraemer. "Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis." Journal of the American Academy of Dermatology 43, no. 4 (2000): S57-S69.
Caputo, R., K. De Boulle, J. Del Rosso, and R. Nowicki. "Prevalence of superficial fungal infections among sports‐active individuals: results from the Achilles survey, a review of the literature." Journal of the European Academy of Dermatology and Venereology 15, no. 4 (2001): 312-316.
Choi, Ki-Choon, Je-Yong Bang, Pyoung-Il Kim, Chan Kim, and Chae-Eun Song. "Amphotericin B-incorporated polymeric micelles composed of poly (d, l-lactide-co-glycolide)/dextran graft copolymer." International journal of pharmaceutics 355, no. 1-2 (2008): 224-230.
Cilurzo, Francesco, Francesca Selmin, Chiara GM Gennari, Luisa Montanari, and Paola Minghetti. "Application of methyl methacrylate copolymers to the development of transdermal or loco-regional drug delivery systems." Expert opinion on drug delivery 11, no. 7 (2014): 1033-1045.
De Berker, D. A. R., R. Baran, and R. P. R. Dawber. "Normal nail anatomy and physical signs in nail disease." Handbook of Diseases of the Nails and their Management. Blackwell Science Ltd, Oxford, 1995a 131 (1995).
Elewski, Boni E. "Onychomycosis: pathogenesis, diagnosis, and management." Clinical microbiology reviews 11, no. 3 (1998): 415-429.
Elewski, Boni E. "Onychomycosis: pathogenesis, diagnosis, and management." Clinical microbiology reviews 11, no. 3 (1998): 415-429.
ELEZOVIĆ, A., S. Hadžović, Š. HADŽIDEDIĆ, and S. Kostić. "Characterization of antifungal nail lacquer formulations containing fluconazole." Scientia Pharmaceutica 78, no. 3 (2010): 624.
Elkeeb, Rania, Ali AliKhan, Laila Elkeeb, Xiaoying Hui, and Howard I. Maibach. "Transungual drug delivery: current status." International journal of pharmaceutics 384, no. 1-2 (2010): 1-8.
Faergemann, J., and R. Baran. "Epidemiology, clinical presentation and diagnosis of onychomycosis." British Journal of Dermatology 149 (2003): 1-4.
Fortune, D. G., C. J. Main, T. M. O'sullivan, and C. E. M. Griffiths. "Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis‐specific stress." British Journal of Dermatology 137, no. 5 (1997): 755-760.
Godge, Ganesh Raosaheb, S. C. Bharat, A. B. Shaikh, B. B. Randhawan, M. A. Raskar, and S. N. Hiremath. "Formulation Perspectives in Topical Antifungal Drug Therapy: A Review." Journal of Drug Delivery and Therapeutics 13, no. 5 (2023): 110-119.
Gupchup, Gouri V., and Joel L. Zatz. "Structural characteristics and permeability properties of the human nail: A review." Journal of cosmetic science 50, no. 6 (1999): 363-385.
Gupta, A. K., C. W. Lynde, H. C. Jain, R. G. Sibbald, B. E. Elewski, C. R. DANIEL III, G. N. Watteel, and R. C. Summerbell. "A higher prevalence of onychomycosis in psoriatics compared with non‐psoriatics: a multicentre study." British Journal of Dermatology 136, no. 5 (1997): 786-789.
Heydendael, Vera MR, Corianne AJM De Borgie, Phyllis I. Spuls, Patrick MM Bossuyt, Jan D. Bos, and Menno A. De Rie. "The burden of psoriasis is not determined by disease severity only." In Journal of Investigative Dermatology Symposium Proceedings, vol. 9, no. 2, pp. 131-135. Elsevier, 2004.
Jodh, Rahul, Mukund Tawar, Aparna Kachewar, Vishal Mahanur, Yash Surekha, and Virendra Atole. "Preparation and Evaluation of Nail Lacquer containing Luliconazole as Ungual Drug Delivery System." International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN) 15, no. 3 (2022).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
